205 related articles for article (PubMed ID: 21790128)
1. Self-assembly of tissue transglutaminase into amyloid-like fibrils using physiological concentration of Ca2+.
Kalhor HR; Shahin V F; Fouani MH; Hosseinkhani H
Langmuir; 2011 Sep; 27(17):10776-84. PubMed ID: 21790128
[TBL] [Abstract][Full Text] [Related]
2. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking.
Konno T; Morii T; Hirata A; Sato S; Oiki S; Ikura K
Biochemistry; 2005 Feb; 44(6):2072-9. PubMed ID: 15697232
[TBL] [Abstract][Full Text] [Related]
3. Functional significance of five noncanonical Ca2+-binding sites of human transglutaminase 2 characterized by site-directed mutagenesis.
Király R; Csosz E; Kurtán T; Antus S; Szigeti K; Simon-Vecsei Z; Korponay-Szabó IR; Keresztessy Z; Fésüs L
FEBS J; 2009 Dec; 276(23):7083-96. PubMed ID: 19878304
[TBL] [Abstract][Full Text] [Related]
4. Structure of natural variant transglutaminase 2 reveals molecular basis of gaining stability and higher activity.
Ha HJ; Kwon S; Jeong EM; Kim CM; Lee KB; Kim IG; Park HH
PLoS One; 2018; 13(10):e0204707. PubMed ID: 30321187
[TBL] [Abstract][Full Text] [Related]
5. Competitive Binding of Magnesium to Calcium Binding Sites Reciprocally Regulates Transamidase and GTP Hydrolysis Activity of Transglutaminase 2.
Jeong EM; Lee KB; Kim GE; Kim CM; Lee JH; Kim HJ; Shin JW; Kwon MA; Park HH; Kim IG
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991788
[TBL] [Abstract][Full Text] [Related]
6. Identification of a specific one amino acid change in recombinant human transglutaminase 2 that regulates its activity and calcium sensitivity.
Kanchan K; Ergülen E; Király R; Simon-Vecsei Z; Fuxreiter M; Fésüs L
Biochem J; 2013 Nov; 455(3):261-72. PubMed ID: 23941696
[TBL] [Abstract][Full Text] [Related]
7. Enzymatic modification of self-assembled peptide structures with tissue transglutaminase.
Collier JH; Messersmith PB
Bioconjug Chem; 2003; 14(4):748-55. PubMed ID: 12862427
[TBL] [Abstract][Full Text] [Related]
8. Tissue transglutaminase in Alzheimer's disease: involvement in pathogenesis and its potential as a therapeutic target.
Wilhelmus MM; de Jager M; Bakker EN; Drukarch B
J Alzheimers Dis; 2014; 42 Suppl 3():S289-303. PubMed ID: 24685636
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the development of tissue transglutaminase (TG2) inhibitors.
Badarau E; Collighan RJ; Griffin M
Amino Acids; 2013 Jan; 44(1):119-27. PubMed ID: 22160259
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori TlyA Forms Amyloid-like Aggregates with Potent Cytotoxic Activity.
Lata K; Chattopadhyay K
Biochemistry; 2015 Jun; 54(23):3649-59. PubMed ID: 26015064
[TBL] [Abstract][Full Text] [Related]
11. New insight into transglutaminase 2 and link to neurodegenerative diseases.
Min B; Chung KC
BMB Rep; 2018 Jan; 51(1):5-13. PubMed ID: 29187283
[TBL] [Abstract][Full Text] [Related]
12. Investigating the inhibitory effects of zinc ions on amyloid fibril formation of hen egg-white lysozyme.
Ma B; Zhang F; Wang X; Zhu X
Int J Biol Macromol; 2017 May; 98():717-722. PubMed ID: 28163126
[TBL] [Abstract][Full Text] [Related]
13. Gallic acid, one of the components in many plant tissues, is a potential inhibitor for insulin amyloid fibril formation.
Jayamani J; Shanmugam G
Eur J Med Chem; 2014 Oct; 85():352-8. PubMed ID: 25105923
[TBL] [Abstract][Full Text] [Related]
14. Detection of Transglutaminase 2 conformational changes in living cell.
Pavlyukov MS; Antipova NV; Balashova MV; Shakhparonov MI
Biochem Biophys Res Commun; 2012 May; 421(4):773-9. PubMed ID: 22548802
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-like Fibril Formation by Trypsin in Aqueous Ethanol. Inhibition of Fibrillation by PEG.
Kotormán M; Simon ML; Borics A; Szabó MR; Szabó K; Szögi T; Fülöp L
Protein Pept Lett; 2015; 22(12):1104-10. PubMed ID: 26428300
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis.
Tatsukawa H; Kojima S
Cell Biol Int; 2010 Feb; 34(3):325-34. PubMed ID: 20192918
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of tissue transglutaminase.
Keillor JW; Apperley KY; Akbar A
Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
[TBL] [Abstract][Full Text] [Related]
18. Substrate preference of transglutaminase 2 revealed by logistic regression analysis and intrinsic disorder examination.
Csosz E; Bagossi P; Nagy Z; Dosztanyi Z; Simon I; Fesus L
J Mol Biol; 2008 Nov; 383(2):390-402. PubMed ID: 18761350
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Wilhelmus MM; van Dam AM; Drukarch B
Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
[TBL] [Abstract][Full Text] [Related]
20. Oligomers, protofibrils and amyloid fibrils from recombinant human lysozyme (rHL): fibrillation process and cytotoxicity evaluation for ARPE-19 cell line.
Ruiz ED; Almada M; Burboa MG; Taboada P; Mosquera V; Valdez MA; Juárez J
Colloids Surf B Biointerfaces; 2015 Feb; 126():335-43. PubMed ID: 25618793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
